Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/10/23
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023GlobeNewsWire • 08/04/23
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research CollaborationGlobeNewsWire • 08/03/23
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study's Independent Interim Review Committee Recommends Continuing StudyGlobeNewsWire • 05/10/23
Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023GlobeNewsWire • 05/04/23
Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson's DiseaseGlobeNewsWire • 04/04/23
Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023GlobeNewsWire • 03/28/23
Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1GlobeNewsWire • 02/06/23
Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery CollaborationGlobeNewsWire • 12/08/22
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/11/22